Baseline characteristics of 17 patients with APS and APS nephropathy on kidney biopsy
| . | . | APS diagnostic criteria* . | . | . | . | . | . | . | . | . | . | Ex vivo C5b9 formation . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Kidney biopsy, y . | Laboratory . | Extrarenal manifestations (y) . | Age, y . | Sex . | SCr, µmol/L . | uRBC . | uP, g/d . | Plts, g/L . | C4, g/L (0.11)† . | C3, g/L (0.75)† . | CPFA, % (75)† . | % vs normal . | P . |
| 01 | 1984 | aCL | — | 48 | M | 80 | – | 1.90 | WNR | 0.30 | 1.36 | >125 | Normal | NS |
| 02 | 1985 | aCL | — | 45 | M | 217 | – | 1.94 | WNR | 0.26 | 1.10 | >125 | 60 | NS |
| 03 | 1985 | LAC, β2GPI, aCL | CAPS‡ (1986) | 50 | M | 223 | – | 0.78 | 93 | ND | ND | ND | ND | |
| 04 | 1986 | β2GPI, aCL | AT (2001), pregnancy | 28 | F | 75 | – | 1.11 | WNR | 0.14 | 0.78 | ND | 109 | NS |
| 05 | 1988 | aCL | AT (2004) | 38 | M | 214 | – | 1.02 | 314 | 0.20 | 1.30 | 3 | 63 | NS |
| 06 | 1988 | LAC, aCL | AT (1990) | 58 | F | 168 | + | 0.38 | 108 | 0.07 | 0.55 | 58 | 117 | NS |
| 07 | 1999 | β2GPI, aCL | VT (1995) | 26 | F | 657 | + | 1.85 | 83 | ND | ND | ND | ND | |
| 08 | 1999 | LAC, β2GPI, aCL | VT (1995) | 53 | M | 155 | – | 4.80 | 93 | 0.18 | 1.04 | 47 | 127 | NS |
| 09 | 2000 | LAC, β2GPI, aCL | — | 26 | M | 119 | – | 0.06 | 152 | 0.15 | 0.93 | ND | 161 | NS |
| 10 | 2000 | LAC, aCL | Pregnancy | 45 | F | 197 | – | 1.20 | 101 | 0.09 | 0.60 | 61 | 189 | .01 |
| 11 | 2002 | aCL | — | 62 | M | 216 | + | 3.64 | 333 | 0.11 | 0.72 | 57 | 103 | NS |
| 12 | 2005 | β2GPI, aCL | — | 73 | F | 284 | + | 1.02 | 97 | 0.13 | 0.73 | 103 | 101 | NS |
| 13 | 2007 | aCL | — | 67 | M | 276 | + | 13.06 | WNR | 0.37 | 1.18 | 122 | 96 | NS |
| 14 | 2007 | β2GPI, aCL | VT (2002) | 27 | F | 69 | + | 0.48 | 314 | 0.16 | 1.09 | 71 | 71 | NS |
| 15 | 2010 | LAC, aCL | — | 19 | F | 103 | – | 0.21 | WNR | 0.11 | 1.02 | 109 | 160 | NS |
| 16 | 2012 | β2GPI, aCL | — | 47 | M | 188 | – | 3.95 | 101 | 0.12 | 1.03 | 33 | 123 | NS |
| 17 | 2014 | LAC, β2GPI, aCL | VT (1998), AT‡ (2014) | 39 | F | 266 | – | 2.72 | 51 | ND | ND | >125 | 78 | NS |
| . | . | APS diagnostic criteria* . | . | . | . | . | . | . | . | . | . | Ex vivo C5b9 formation . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Kidney biopsy, y . | Laboratory . | Extrarenal manifestations (y) . | Age, y . | Sex . | SCr, µmol/L . | uRBC . | uP, g/d . | Plts, g/L . | C4, g/L (0.11)† . | C3, g/L (0.75)† . | CPFA, % (75)† . | % vs normal . | P . |
| 01 | 1984 | aCL | — | 48 | M | 80 | – | 1.90 | WNR | 0.30 | 1.36 | >125 | Normal | NS |
| 02 | 1985 | aCL | — | 45 | M | 217 | – | 1.94 | WNR | 0.26 | 1.10 | >125 | 60 | NS |
| 03 | 1985 | LAC, β2GPI, aCL | CAPS‡ (1986) | 50 | M | 223 | – | 0.78 | 93 | ND | ND | ND | ND | |
| 04 | 1986 | β2GPI, aCL | AT (2001), pregnancy | 28 | F | 75 | – | 1.11 | WNR | 0.14 | 0.78 | ND | 109 | NS |
| 05 | 1988 | aCL | AT (2004) | 38 | M | 214 | – | 1.02 | 314 | 0.20 | 1.30 | 3 | 63 | NS |
| 06 | 1988 | LAC, aCL | AT (1990) | 58 | F | 168 | + | 0.38 | 108 | 0.07 | 0.55 | 58 | 117 | NS |
| 07 | 1999 | β2GPI, aCL | VT (1995) | 26 | F | 657 | + | 1.85 | 83 | ND | ND | ND | ND | |
| 08 | 1999 | LAC, β2GPI, aCL | VT (1995) | 53 | M | 155 | – | 4.80 | 93 | 0.18 | 1.04 | 47 | 127 | NS |
| 09 | 2000 | LAC, β2GPI, aCL | — | 26 | M | 119 | – | 0.06 | 152 | 0.15 | 0.93 | ND | 161 | NS |
| 10 | 2000 | LAC, aCL | Pregnancy | 45 | F | 197 | – | 1.20 | 101 | 0.09 | 0.60 | 61 | 189 | .01 |
| 11 | 2002 | aCL | — | 62 | M | 216 | + | 3.64 | 333 | 0.11 | 0.72 | 57 | 103 | NS |
| 12 | 2005 | β2GPI, aCL | — | 73 | F | 284 | + | 1.02 | 97 | 0.13 | 0.73 | 103 | 101 | NS |
| 13 | 2007 | aCL | — | 67 | M | 276 | + | 13.06 | WNR | 0.37 | 1.18 | 122 | 96 | NS |
| 14 | 2007 | β2GPI, aCL | VT (2002) | 27 | F | 69 | + | 0.48 | 314 | 0.16 | 1.09 | 71 | 71 | NS |
| 15 | 2010 | LAC, aCL | — | 19 | F | 103 | – | 0.21 | WNR | 0.11 | 1.02 | 109 | 160 | NS |
| 16 | 2012 | β2GPI, aCL | — | 47 | M | 188 | – | 3.95 | 101 | 0.12 | 1.03 | 33 | 123 | NS |
| 17 | 2014 | LAC, β2GPI, aCL | VT (1998), AT‡ (2014) | 39 | F | 266 | – | 2.72 | 51 | ND | ND | >125 | 78 | NS |
aCL, anti-cardiolipin antibodies; AT, arterial thrombosis; β2GP1, anti-beta2 glycoprotein-1 antibodies; CAPS, catastrophic APS; CPFA, classical pathway functional activity; F, female; LAC, lupus anticoagulant; M, male; ND, not determined; NS, not significant; SCr, serum creatinine; uP, proteinuria; uRBC, hematuria; VT, venous thrombosis; WNR, within normal range.
Diagnostic criteria are from Miyakis et al.5
Lower limit of normal.
12 mo from kidney biopsy.